Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
暂无分享,去创建一个
G. Argenziano | G. Fabbrocini | M. Napolitano | C. Patruno | G. Pellacani | C. Foti | L. Bonzano | S. Ferrucci | G. Calabrese | S. Nisticò | S. Ribero | E. Di Leo | E. Nettis | L. Macchia | F. Rongioletti | M. Ortoncelli | D. Di Bona | P. Romita | V. Piras | S. Tavecchio | C. Detoraki | M. Carbonara
[1] G. Fabbrocini,et al. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study , 2020, Clinical and experimental dermatology.
[2] G. Canonica,et al. Efficacy of dupilumab in atopic comorbidities associated with moderate‐to‐severe adult atopic dermatitis , 2020, Allergy.
[3] G. Fabbrocini,et al. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults , 2020, Dermatologic therapy.
[4] G. Casazza,et al. Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience , 2020, Journal of clinical medicine.
[5] A. Ganesan,et al. Real‐world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records , 2020, International journal of dermatology.
[6] J. Carrascosa,et al. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment. , 2020, Actas dermo-sifiliograficas.
[7] G. Fabbrocini,et al. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Clinical Phenotype of Adult Atopic Dermatitis. , 2020, Dermatitis : contact, atopic, occupational, drug.
[8] M. D. de Bruin‐Weller,et al. Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry , 2019, Allergy.
[9] A. Murphy,et al. Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation , 2019, Allergy.
[10] S. Guerriero,et al. Dupilumab-Induced Bilateral Cicatricial Ectropion in Real Life. , 2019, The journal of allergy and clinical immunology. In practice.
[11] J. Sastre,et al. Treatment of moderate‐to‐severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series , 2019, The British journal of dermatology.
[12] T. Nijsten,et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data , 2019, The British journal of dermatology.
[13] T. Agner,et al. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.
[14] S. Williamson,et al. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks , 2019, The British journal of dermatology.
[15] J. Giovannelli,et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. , 2019, Journal of the American Academy of Dermatology.
[16] A. Didier,et al. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real‐life practice , 2019, The British journal of dermatology.
[17] John D. Davis,et al. Conjunctivitis in dupilumab clinical trials , 2019, The British journal of dermatology.
[18] J. Pereyra-Rodríguez,et al. Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric series , 2019, Dermatologic therapy.
[19] P. Lio,et al. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis , 2018, JAMA dermatology.
[20] M. Låzaro,et al. Basic Skin Care and Topical Therapies for Atopic Dermatitis: Essential Approaches and Beyond. , 2018, Journal of investigational allergology & clinical immunology.
[21] I. Dávila,et al. Dupilumab: A New Paradigm for the Treatment of Allergic Diseases. , 2018, Journal of investigational allergology & clinical immunology.
[22] M. Cork,et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) , 2018, The British journal of dermatology.
[23] A. Muraro,et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[24] M. D. de Bruin‐Weller,et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. , 2018, The journal of allergy and clinical immunology. In practice.
[25] J. Silverberg,et al. Phenotypical Differences of Childhood- and Adult-Onset Atopic Dermatitis. , 2017, The journal of allergy and clinical immunology. In practice.
[26] G. Yancopoulos,et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.
[27] Donald Y M Leung,et al. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. , 2017, The Journal of allergy and clinical immunology.
[28] Tadeusz Pawelczyk,et al. Expression of Cornified Envelope Proteins in Skin and Its Relationship with Atopic Dermatitis Phenotype. , 2017, Acta dermato-venereologica.
[29] J. Silverberg,et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.
[30] H. Williams,et al. Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) , 2016, The British journal of dermatology.
[31] C. Motala,et al. Management of difficult-to-treat atopic dermatitis. , 2013, The journal of allergy and clinical immunology. In practice.
[32] J. Schmitt,et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference , 2012, Allergy.
[33] M. Graeber,et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis , 2001, Experimental dermatology.
[34] John D. Davis,et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study , 2020 .
[35] P. Ferrinho,et al. Quality of Life and characterization of patients with atopic dermatitis in Portugal - QUADEP study. , 2019, Journal of investigational allergology & clinical immunology.
[36] J F Silvestre Salvador,et al. Atopic Dermatitis in Adults: A Diagnostic Challenge. , 2017, Journal of investigational allergology & clinical immunology.
[37] J. Schmitt,et al. What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. , 2017, Acta dermato-venereologica.
[38] J. Silverberg,et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. , 2015, The Journal of investigative dermatology.